Teva Pharmaceutical Industries Limited (TEVA)
| Previous Close | 15.74 |
| Open | 15.71 |
| Bid | 16.18 x 2200 |
| Ask | 16.19 x 1000 |
| Day's Range | 15.53 - 16.25 |
| 52 Week Range | 7.09 - 16.25 |
| Volume | |
| Avg. Volume | 9,815,675 |
| Market Cap | 18.298B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | N/A |
- Business Wire
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEL AVIV, Israel, May 08, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2024.
- Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, May 08, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-‘749 met its primary endpoint as measured by a change in the
- Business Wire
Teva to Present at the 2024 Bank of America Healthcare Conference
TEL AVIV, Israel, May 02, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time).
